{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:38:03Z","timestamp":1792791483818,"version":"4.5.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T00:00:00Z","timestamp":1753401600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA258302"],"award-info":[{"award-number":["R01CA258302"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA269644"],"award-info":[{"award-number":["R01CA269644"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA279398"],"award-info":[{"award-number":["R01CA279398"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.ymthe.2025.07.042","type":"journal-article","created":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T15:44:54Z","timestamp":1753803894000},"page":"5017-5027","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["CD93 blockade overcomes sunitinib resistance in pancreatic neuroendocrine tumors"],"prefix":"10.1016","volume":"33","author":[{"given":"Yi","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Torphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elliott J.","family":"Yee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujie","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiwei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyi","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleanor","family":"Eck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taichi","family":"Terai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard D.","family":"Schulick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1434-6590","authenticated-orcid":false,"given":"Yuwen","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2025.07.042_bib1","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1200\/JCOOP.20.00010","article-title":"Understanding the Management and Treatment of Well-Differentiated Pancreatic Neuroendocrine Tumors: A Clinician's Guide to a Complex Illness","volume":"16","author":"Li","year":"2020","journal-title":"JCO Oncol. Pract."},{"key":"10.1016\/j.ymthe.2025.07.042_bib2","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1146\/annurev-med-042320-011248","article-title":"Progress in the Management of Pancreatic Neuroendocrine Tumors","volume":"73","author":"Chang","year":"2022","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.ymthe.2025.07.042_bib3","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1046\/j.1365-2559.1998.00321.x","article-title":"Expression of vascular endothelial growth factor in digestive neuroendocrine tumours","volume":"32","author":"Terris","year":"1998","journal-title":"Histopathology"},{"key":"10.1016\/j.ymthe.2025.07.042_bib4","first-page":"327","article-title":"In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic\/pharmacodynamic relationship","volume":"9","author":"Mendel","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2025.07.042_bib5","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1056\/NEJMoa1003825","article-title":"Sunitinib malate for the treatment of pancreatic neuroendocrine tumors","volume":"364","author":"Raymond","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.07.042_bib6","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/annonc\/mdw561","article-title":"Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study","volume":"28","author":"Faivre","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ymthe.2025.07.042_bib7","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.ccr.2005.09.005","article-title":"Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors","volume":"8","author":"Casanovas","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ymthe.2025.07.042_bib8","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/nrc2442","article-title":"Modes of resistance to anti-angiogenic therapy","volume":"8","author":"Bergers","year":"2008","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ymthe.2025.07.042_bib9","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.cell.2019.01.021","article-title":"VEGF in Signaling and Disease: Beyond Discovery and Development","volume":"176","author":"Apte","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2025.07.042_bib10","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20194949","article-title":"Targeting Angiogenesis in Pancreatic Neuroendocrine Tumors: Resistance Mechanisms","volume":"20","author":"Pozas","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymthe.2025.07.042_bib11","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.ccr.2009.01.027","article-title":"Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis","volume":"15","author":"Paez-Ribes","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ymthe.2025.07.042_bib12","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1158\/2159-8290.CD-11-0240","article-title":"Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors","volume":"2","author":"Sennino","year":"2012","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ymthe.2025.07.042_bib13","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abc8922","article-title":"Blockade of the CD93 pathway normalizes tumor vasculature to facilitate drug delivery and immunotherapy","volume":"13","author":"Sun","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2025.07.042_bib14","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.matbio.2017.08.003","article-title":"Dissecting the CD93-Multimerin 2 interaction involved in cell adhesion and migration of the activated endothelium","volume":"64","author":"Galvagni","year":"2017","journal-title":"Matrix Biol."},{"key":"10.1016\/j.ymthe.2025.07.042_bib15","doi-asserted-by":"crossref","first-page":"6097","DOI":"10.1038\/onc.2017.214","article-title":"Multimerin-2 is a ligand for group 14 family C-type lectins CLEC14A, CD93 and CD248 spanning the endothelial pericyte interface","volume":"36","author":"Khan","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.ymthe.2025.07.042_bib16","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1158\/1535-7163.MCT-09-0470","article-title":"Efficacy of IGFBP7 for treatment of metastatic melanoma and other cancers in mouse models and human cell lines","volume":"8","author":"Wajapeyee","year":"2009","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ymthe.2025.07.042_bib17","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2024.1421438","article-title":"Insulin-like growth factor-binding protein 7 (IGFBP7): A microenvironment-dependent regulator of angiogenesis and vascular remodeling","volume":"12","author":"Lit","year":"2024","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.ymthe.2025.07.042_bib18","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010554","article-title":"CD93 blockade promotes effector T-cell infiltration and facilitates adoptive cell therapy in solid tumors","volume":"13","author":"Sun","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ymthe.2025.07.042_bib19","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/315115a0","article-title":"Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin\/simian virus 40 oncogenes","volume":"315","author":"Hanahan","year":"1985","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2025.07.042_bib20","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1172\/JCI200317929","article-title":"Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors","volume":"111","author":"Bergers","year":"2003","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymthe.2025.07.042_bib21","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1126\/science.284.5415.808","article-title":"Effects of angiogenesis inhibitors on multistage carcinogenesis in mice","volume":"284","author":"Bergers","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2025.07.042_bib22","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1200\/JCO.2005.07.093","article-title":"A multitargeted, metronomic, and maximum-tolerated dose \"chemo-switch\" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer","volume":"23","author":"Pietras","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2025.07.042_bib23","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.ccell.2014.10.006","article-title":"Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia","volume":"26","author":"Jain","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ymthe.2025.07.042_bib24","first-page":"928","article-title":"Glucose transporter glut-1 expression correlates with tumor hypoxia and predicts metastasis-free survival in advanced carcinoma of the cervix","volume":"7","author":"Airley","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2025.07.042_bib25","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/ijc.10904","article-title":"GLUT-1 and CAIX as intrinsic markers of hypoxia in carcinoma of the cervix: relationship to pimonidazole binding","volume":"104","author":"Airley","year":"2003","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ymthe.2025.07.042_bib26","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1002\/onco.13885","article-title":"Sunitinib and Evofosfamide (TH-302) in Systemic Treatment-Naive Patients with Grade 1\/2 Metastatic Pancreatic Neuroendocrine Tumors: The GETNE-1408 Trial","volume":"26","author":"Grande","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.ymthe.2025.07.042_bib27","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s11523-020-00784-0","article-title":"Updated Efficacy and Safety Outcomes for Patients with Well-Differentiated Pancreatic Neuroendocrine Tumors Treated with Sunitinib","volume":"16","author":"Fazio","year":"2021","journal-title":"Target. Oncol."},{"key":"10.1016\/j.ymthe.2025.07.042_bib28","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1158\/1535-7163.MCT-17-0136","article-title":"Autophagy Inhibition Improves Sunitinib Efficacy in Pancreatic Neuroendocrine Tumors via a Lysosome-dependent Mechanism","volume":"16","author":"Wiedmer","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ymthe.2025.07.042_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2023.100929","article-title":"Sunitinib resistance in renal cell carcinoma: From molecular mechanisms to predictive biomarkers","volume":"67","author":"Jin","year":"2023","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.ymthe.2025.07.042_bib30","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1172\/JCI24612","article-title":"Rapid vascular regrowth in tumors after reversal of VEGF inhibition","volume":"116","author":"Mancuso","year":"2006","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymthe.2025.07.042_bib31","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1038\/onc.2011.487","article-title":"MULTIMERIN2 impairs tumor angiogenesis and growth by interfering with VEGF-A\/VEGFR2 pathway","volume":"31","author":"Lorenzon","year":"2012","journal-title":"Oncogene"},{"key":"10.1016\/j.ymthe.2025.07.042_bib32","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s10456-024-09907-x","article-title":"Group XIV C-type lectins: emerging targets in tumor angiogenesis","volume":"27","author":"Yee","year":"2024","journal-title":"Angiogenesis"}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001625005787?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001625005787?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:44:18Z","timestamp":1792788258000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001625005787"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":32,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S1525001625005787"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2025.07.042","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CD93 blockade overcomes sunitinib resistance in pancreatic neuroendocrine tumors","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2025.07.042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}